Premature Ejaculation Linked to Hypoglycemic Variability in T1DM

This article originally appeared here.
Share this content:
Premature Ejaculation Linked to Hypoglycemic Variability in T1DM
Premature Ejaculation Linked to Hypoglycemic Variability in T1DM

MONDAY, Dec. 8, 2014 (HealthDay News) -- Higher glycemic variability in the hypoglycemic domain is associated with premature ejaculation (PE) in young males with type 1 diabetes (T1DM), although prevalence of PE is similar for young males with and without T1DM, according to a study published online Nov. 26 in the Journal of Sexual Medicine.

Giuseppe Bellastella, M.D., Ph.D., from the Second University of Naples in Italy, and colleagues examined the prevalence of PE in type 1 diabetes. Data were collected from 100 male patients with type 1 diabetes (age, <40 years) and 51 age-matched controls without diabetes. Blood glucose variability was assessed in a subgroup of 30 patients with diabetes (20 with PE and 10 without). The premature ejaculation diagnostic tool (PEDT) and the self-estimated intravaginal ejaculatory latency time (IELT) were used to assess the presence of PE.

The researchers noted no significant difference in PE prevalence between the groups: Pathological values of PEDT score and IELT score were observed in 24 percent of patients with diabetes and in 23.5 percent of controls. Hemoglobin A1c was significantly associated with the PEDT score (P = 0.006) and IELT (P = 0.01). The PEDT score correlated with low blood glucose indices but not with the standard deviation of blood glucose, mean amplitude of glycemic excursions, or low blood glucose indices in the subgroup assessed for glucose variability.

"In diabetic patients with PE, a higher glycemic variability in the hypoglycemic domain is significantly associated with the PEDT score," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths